Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Operating Leases (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Operating Leases for 3 consecutive years, with $4.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Operating Leases rose 158.37% to $4.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $4.7 million, a 158.37% increase, with the full-year FY2024 number at $8.0 million, up 625.05% from a year prior.
  • Operating Leases was $4.7 million for Q3 2025 at Inhibrx Biosciences, down from $5.3 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $8.0 million in Q4 2024 to a low of $1.1 million in Q4 2023.
  • A 3-year average of $4.2 million and a median of $4.7 million in 2025 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: soared 625.05% in 2024, then soared 146.02% in 2025.
  • Inhibrx Biosciences' Operating Leases stood at $1.1 million in 2023, then skyrocketed by 625.05% to $8.0 million in 2024, then plummeted by 41.09% to $4.7 million in 2025.
  • Per Business Quant, the three most recent readings for INBX's Operating Leases are $4.7 million (Q3 2025), $5.3 million (Q2 2025), and $5.9 million (Q1 2025).